SCHEMBL1663779

SCHEMBL1663779

CCOC(=O)C1CCCC1n1c(C(C)C)nc2cc(O)ccc2c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.42
NPSR1 Q6W5P4 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 4/20 0.35
PLA2G1B P04054 2/20 0.35
ATG4B Q9Y4P1 2/20 0.35
JAK1 P23458 1/20 0.35
THRB P10828 1/20 0.35
ESR1 P03372 2/20 0.35
GAA P10253 2/20 0.35
HSD17B10 Q99714 2/20 0.34
ESR2 Q92731 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
RAD52 P43351 1/20 0.34
CASP7 P55210 1/20 0.34
TSHR P16473 1/20 0.34
OPRM1 P35372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1664215 0.77 TRPV1 (0.55) TRPV1NPSR1SMN1; SMN2ALDH1A1PLA2G1B
SCHEMBL1666090 0.76 TRPV1 (0.54) TRPV1NPSR1SMN1; SMN2ALDH1A1PLA2G1B
SCHEMBL1663627 0.72 TRPV1 (0.49) TRPV1ALDH1A1PLA2G1BATG4BJAK1
SCHEMBL1663935 0.72 TRPV1 (0.49) TRPV1NPSR1ALDH1A1PLA2G1BATG4B
SCHEMBL1663306 0.69 TRPV1 (0.51) TRPV1NPSR1ALDH1A1PLA2G1BATG4B
SCHEMBL1663421 0.68 TRPV1 (0.54) TRPV1NPSR1SMN1; SMN2ALDH1A1ESR1
SCHEMBL1663631 0.67 TRPV1 (0.58) TRPV1ALDH1A1ESR1GAAHSD17B10
SCHEMBL1663914 0.66 TRPV1 (0.50) TRPV1SMN1; SMN2ALDH1A1ESR1ESR2
SCHEMBL1664148 0.65 TRPV1 (0.54) TRPV1NPSR1ALDH1A1ESR1GAA
SCHEMBL1664439 0.65 TRPV1 (0.74) TRPV1NPSR1SMN1; SMN2ALDH1A1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885NPSR1 50/4885SMN1; SMN2 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.